Covered recipient · General Payments record
NICOLE RENE SCHMIEDT
Eye and Vision Services Providers Optometrist
General Payments · PY2020–2024
$995.78
- Reported across 39 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $379.86 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| CooperVision Inc. | $169.15 | 5 |
| Alcon Laboratories Inc | $77.51 | 4 |
| BIOTISSUE HOLDINGS INC. | $42.84 | 2 |
| Johnson & Johnson Vision Care, Inc. | $27.60 | 1 |
| Tarsus Pharmaceuticals, Inc. | $17.42 | 1 |
| Amgen Inc. | $15.61 | 1 |
| RxSight Inc | $15.29 | 1 |
| Oyster Point Pharma, Inc. | $14.44 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alcon Vision LLC | $16.44 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110696459 | CMS |
| Alcon Vision LLC | $20.58 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110696463 | CMS |
| Alcon Vision LLC | $21.74 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110696465 | CMS |
| Alcon Vision LLC | $18.75 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110696461 | CMS |
| Amgen Inc. | $15.61 | 02/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116095166 | CMS |
| BIOTISSUE HOLDINGS INC. | $22.61 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148789265 | CMS |
| BIOTISSUE HOLDINGS INC. | $20.23 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148776541 | CMS |
| CooperVision Inc. | $22.00 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145526229 | CMS |
| CooperVision Inc. | $5.80 | 07/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145526263 | CMS |
| CooperVision Inc. | $115.72 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145526279 | CMS |
| CooperVision Inc. | $24.18 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145526299 | CMS |
| CooperVision Inc. | $1.45 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145526301 | CMS |
| Johnson & Johnson Vision Care, Inc. | $27.60 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077732330 | CMS |
| Oyster Point Pharma, Inc. | $14.44 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147398994 | CMS |
| RxSight Inc | $15.29 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144227646 | CMS |
| Tarsus Pharmaceuticals, Inc. | $17.42 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139130444 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.